BOSTON--(BUSINESS WIRE)--Nov. 16, 2005--Point Therapeutics, Inc. (NASDAQ:POTP) presented positive results from the company's Phase 2 study of talabostat in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) in a poster session at the AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, PA.
The trial enrolled 55 patients--42 of whom met evaluability criteria for response. Five patients demonstrated a clinical response to treatment as defined by World Health Organization criteria (a 50% or greater reduction in tumor size) for a response rate of 11.9%. Two of these patients had a complete response, defined as a complete disappearance of their tumor. The first complete responder was observed in March 2005 and the second in April 2005; both patients continue to be in complete response. The current Kaplan-Meier estimate of median progression-free survival is 4.2 months and median survival is estimated at 8.4 months. To date, the one-year survival rate is 48% for the 31 patients who have been in the study for at least one year.
